# US 8,277,800 B2 · Methods of treating a deficiency of functional tripeptidyl peptidase I (CLN2) protein

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,277,800 B2
- Document ID: US8277800B2
- Status: Granted
- Kind: B2
- Application number: 13/220,572
- Filed: 2011-08-29
- Published: 2012-01-19
- Granted: 2012-10-02
- Earliest claimed: 2000-05-11
- Assignees: University of Medicine and Dentistry of New Jersey
- Inventors: Peter Lobel; David Sleat
- Web page: https://patentgrep.com/patent/US8277800B2

## CPC

- A61K 38/43: Enzymes; Proenzymes; Derivatives thereof
- A61K 38/4813: {Exopeptidases (3.4.11. to 3.4.19)}
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C12Y 304/14009: Tripeptidyl-peptidase I (3.4.14.9)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12Y: ENZYMES

## Abstract

The present invention relates to a method for treating a patient having disorder characterized by a deficient amount of functional CLN2 protein in the affected cells, which comprises administering to the patient an amount of CLN2 protein effective to reduce or eliminate the symptoms caused by the deficiency in CLN2 protein.

## Claims

### Claim 1

A method for treating a patient having a disorder characterized by a deficient amount of functional tripeptidyl peptidase I (CLN2) protein in the affected cells, which comprises administering to the patient an amount of recombinant human CLN2 protein effective to reduce or eliminate the symptoms caused by the deficiency in CLN2 protein, wherein the recombinant human CLN2 protein:
(a) is an inactive proenzyme; and
(b) is mannose-6-phosphorylated.

### Claim 2 (depends on 1)

A method of claim 1 wherein the disorder is characterized by accumulation of mitochondrial ATP synthase subunit c in the lysosomes of the affected cells.

### Claim 3 (depends on 2)

A method of claim 2 wherein the affected cells are neuronal cells.

### Claim 4 (depends on 2)

A method of claim 2 wherein the level of mitochondrial ATP synthase subunit c is reduced by administration of the recombinant human CLN2 protein.

### Claim 5 (depends on 3)

A method of claim 3 wherein the disorder is late infantile neuronal ceroid lipofuscinosis (LINCL).

### Claim 6 (depends on 1)

A method of claim 1 wherein the recombinant human CLN2 protein is administered by injection.

### Claim 7 (depends on 1)

A method of claim 1 wherein the recombinant human CLN2 protein is administered with an uptake inhibitor, wherein the uptake inhibitor is mannose-6-phosphate.

### Claim 8 (depends on 6)

A method of claim 6 wherein the effective amount of recombinant human CLN2 protein is such that the affected cells receive from about 1.0 to about 100 nM of recombinant human CLN2 protein.

### Claim 9 (depends on 7)

A method of claim 7 wherein the effective amount of recombinant human CLN2 protein is such that the affected cells receive from about 1.0 to about 100 nM of recombinant human CLN2 protein.

### Claim 10 (depends on 6)

A method of claim 6 wherein the injection is intracranial.

### Claim 11 (depends on 1)

A method of claim 1 wherein the recombinant human CLN2 protein is administered in a controlled release system.

### Claim 12 (depends on 1)

A method of claim 1 wherein the recombinant human CLN2 protein is delivered to lysosomes of the affected cells.

### Claim 13 (depends on 12)

A method of claim 12 wherein the delivery to the lysosomes of the affected cells is by mannose-6-phosphate mediated endocytosis.

### Claim 14 (depends on 1)

A method of claim 1 wherein the recombinant human CLN2 protein has an apparent size of about 65 kDa by denaturing PAGE.

### Claim 15 (depends on 1)

A method of claim 1 wherein the recombinant human CLN2 protein is produced in Chinese hamster ovary (CHO) cells.

### Claim 16 (depends on 1)

A method of claim 1 wherein the patient is a human.
